H5O0.F Argent BioPharma Limited
- Market cap
- EUR 1.24M
- P/E
- -
- P/B
- 8.64x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is H5O0.F undervalued?
Graham numberThe Graham number of Argent BioPharma Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Argent BioPharma Limited fundamental analysis
No fundamental analysis for Argent BioPharma Limited yet.
Argent BioPharma Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Argent BioPharma Limited
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA c…
Full company profileArgent BioPharma Limited financial statements
Argent BioPharma Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 4.73M | 3.39M | 891K | 583K | 161K |
| Gross Profit | 1.81M | 1.45M | 204K | 446K | -39.6K |
| Operating Income | -14.3M | -15.6M | -18.3M | -15.4M | -7.44M |
| EBITDA | -16.7M | -20.0M | -15.8M | -17.0M | -7.51M |
| Net Income | -16.8M | -20.8M | -17.5M | -17.8M | -7.71M |
| EPS | -6.53 | -6.21 | -0.39 | -0.25 | -0.07 |
| Balance Sheet | |||||
| Total Assets | 23.6M | 9.88M | 10.8M | 2.47M | 1.29M |
| Total Liabilities | 13.7M | 18.0M | 16.6M | 11.1M | 10.7M |
| Shareholders' Equity | 11.2M | -7.51M | -5.15M | -8.63M | -9.45M |
| Cash & Short-term Investments | 1.79M | 240K | 703K | 1.02M | 141K |
| Cash Flow | |||||
| Capital Expenditure | 4.02M | 739K | 140K | 2.23K | 1.61K |
| Free Cash Flow | -14.8M | -11.3M | -14.4M | -9.28M | -4.03M |
| Ratios | |||||
| ROE | -149.2% | - | - | - | - |
| ROA | -71.2% | -210.8% | -162.5% | -723.1% | -595.4% |
| Net Profit Margin | -354.3% | -614.7% | -1,967.3% | -3,058.4% | -4,783.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Argent BioPharma Limited dividends
Argent BioPharma Limited has not paid dividends in the last 7 fiscal years.
Last stock split: 1:1000 on Oct 30, 2023.
Who owns Argent BioPharma Limited
- Insiders 66.03%
- Institutions 0.00%
- Public & others 33.98%
- Shares outstanding 118M
- Free float 40.1M
Argent BioPharma Limited company profile
- Company name
- Argent BioPharma Limited
- Ticker
- H5O0.F
- ISIN
- AU0000326647
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- June
- Address
- 295 Rokeby Road, Subiaco, WA, Australia, 6008
- Phone
- 61 8 6555 2950
- Website
- argentbiopharma.com
About Argent BioPharma Limited
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Argent BioPharma Limited management
9- Mr. Roby Reuven ZomerCo-Founder, CEO & Chairman · born 1980
- Mr. Andrew Chapman B.Bus(Econ), DFP, GradDipAppFinNon Executive Director · born 1975
- Mr. Shachar ShimonyGroup General Counsel
- Mr. Amir PolakChief Pharmaceutical Development Officer
- Dr. Nadya LisovoderChief Medical Officer
- Ms. Sasha FriedmanHead of Information Systems
- Yair TalChief Information Security Officer
- Sanja CacovichHead of Non-Pharmaceutical Operations
- Mr. Rowan Michael HarlandCompany Secretary